Evidence map›Paper›PMID 38379905›Full record

ArticleFrontiers in pharmacology2024

Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection.

Abdelrahim Maen, Betul Gok Yavuz, Yehia I Mohamed, Abdullah Esmail, Jianming Lu, Amr Mohamed, Asfar S Azmi, Mohamed Kaseb, Osama Kasseb, Dan Li and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Abdelrahim Maen *Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston, TX, United States.
Betul Gok Yavuz *Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Yehia I MohamedDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Abdullah EsmailSection of GI Oncology, Houston Methodist Neal Cancer Center, Houston, TX, United States.
Jianming LuCodex BioSolutions Inc., Rockville, MD, United States.
Amr MohamedSeidman Cancer Center, Case Western University, Multidisciplinary NET Treatment, Cleveland, OH, United States.
Asfar S AzmiSchool of Medicine, Wayne State University, Detroit, MI, United States.
Mohamed KasebNovatek Pharmaceuticals, Inc., Houston, TX, United States.
Osama KassebNovatek Pharmaceuticals, Inc., Houston, TX, United States.
Dan LiDepartment of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Michelle GocioNovatek Pharmaceuticals, Inc., Houston, TX, United States.
Mehmet KocakDepartment of Biostatistics and Medical Informatics, International School of Medicine, Istanbul Medipol University, Istanbul, Türkiye.
Abdelhafez SelimPhiladelphia College of Osteopathic Medicine (PCOM), Philadelphia, PA, United States.
Qing MaDepartment of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Ahmed O KasebDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
The University of Texas MD Anderson Cancer Center · USHouston Methodist · USCodex Biosolutions (United States) · USIstanbul Medipol University · TRPhiladelphia College of Osteopathic Medicine · USUniversity Hospitals Seidman Cancer Center · USWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants

Indexed as

CoronavirusCOVID-19COVID-19 and anti-viral agentsfatty acidsThymoquinone TQTQ formula

Identifiers

PMID38379905
PMCPMC10876831
OpenAlexW4391571526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.